Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amicus (FOLD), Azenta (AZTA) and ImmunoGen (IMGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amicus (FOLDResearch Report), Azenta (AZTAResearch Report) and ImmunoGen (IMGNResearch Report).

Amicus (FOLD)

Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Amicus today and set a price target of $11.00. The company’s shares closed last Monday at $6.23, close to its 52-week low of $5.91.

According to TipRanks.com, Shu is ranked 0 out of 5 stars with an average return of -33.5% and a 11.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

Amicus has an analyst consensus of Moderate Buy, with a price target consensus of $14.25, which is a 137.1% upside from current levels. In a report released yesterday, Needham also maintained a Hold rating on the stock.

See the top stocks recommended by analysts >>

Azenta (AZTA)

In a report released today, David Saxon from Needham reiterated a Buy rating on Azenta, with a price target of $94.00. The company’s shares closed last Monday at $64.69, close to its 52-week low of $64.04.

According to TipRanks.com, Saxon is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.8% and a 13.1% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Alphatec Holdings, and Globus Medical.

Currently, the analyst consensus on Azenta is a Strong Buy with an average price target of $100.00.

ImmunoGen (IMGN)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on ImmunoGen today and set a price target of $12.00. The company’s shares closed last Monday at $3.99, close to its 52-week low of $3.83.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.3% and a 32.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Janux Therapeutics Inc.

Currently, the analyst consensus on ImmunoGen is a Moderate Buy with an average price target of $11.50, which is a 155.0% upside from current levels. In a report released yesterday, BMO Capital also reiterated a Buy rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on FOLD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos